Global Bio-chem Technology Group (HKG:0809) expects a net gain (excluding tax effect) of between HK$600 million and HK$800 million for the year 2024, down from HK$4.18 billion a year prior, a Thursday filing with the Hong Kong bourse said.

The biotech firm attributed the lower anticipated net gain mainly to the absence of a one-off gain of roughly HK$4.28 billion on completion of a debt restructuring agreement.